Apellis Pharmaceuticals, Inc. Expected to Post Q2 2025 Earnings of $0.23 Per Share (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Research analysts at Zacks Research upped their Q2 2025 EPS estimates for Apellis Pharmaceuticals in a research note issued to investors on Tuesday, April 23rd. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.23 per share for the quarter, up from their prior forecast of $0.18. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.33) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at $0.45 EPS, Q1 2026 earnings at $1.14 EPS and FY2026 earnings at $3.59 EPS.

Several other equities research analysts have also recently commented on the stock. Oppenheimer boosted their price target on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 30th. JPMorgan Chase & Co. lifted their price target on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Robert W. Baird reissued an “outperform” rating and issued a $81.00 price target on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. The Goldman Sachs Group lifted their price target on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, January 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $92.00 target price on shares of Apellis Pharmaceuticals in a research note on Monday, April 15th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $77.93.

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock opened at $47.93 on Wednesday. The company has a current ratio of 3.10, a quick ratio of 2.50 and a debt-to-equity ratio of 0.48. The company’s 50-day moving average price is $58.61 and its two-hundred day moving average price is $57.37. Apellis Pharmaceuticals has a 52 week low of $19.83 and a 52 week high of $94.75. The stock has a market cap of $5.78 billion, a PE ratio of -10.70 and a beta of 0.88.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.73). Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The business had revenue of $146.38 million for the quarter, compared to analysts’ expectations of $143.34 million. During the same period in the previous year, the business earned ($1.50) earnings per share. The company’s revenue was up 545.9% on a year-over-year basis.

Insider Activity at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 18,681 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $57.18, for a total value of $1,068,179.58. Following the completion of the sale, the director now directly owns 173,998 shares in the company, valued at approximately $9,949,205.64. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, General Counsel David O. Watson sold 906 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $64.14, for a total transaction of $58,110.84. Following the completion of the transaction, the general counsel now directly owns 104,171 shares in the company, valued at $6,681,527.94. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director A. Sinclair Dunlop sold 18,681 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $57.18, for a total value of $1,068,179.58. Following the transaction, the director now owns 173,998 shares of the company’s stock, valued at $9,949,205.64. The disclosure for this sale can be found here. In the last quarter, insiders sold 381,011 shares of company stock valued at $23,463,657. 7.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of APLS. Jennison Associates LLC lifted its holdings in shares of Apellis Pharmaceuticals by 79.8% during the third quarter. Jennison Associates LLC now owns 3,542,209 shares of the company’s stock worth $134,746,000 after buying an additional 1,571,606 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Apellis Pharmaceuticals by 109.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock valued at $128,400,000 after purchasing an additional 1,121,497 shares in the last quarter. Norges Bank acquired a new position in shares of Apellis Pharmaceuticals in the fourth quarter valued at $56,640,000. Price T Rowe Associates Inc. MD raised its stake in shares of Apellis Pharmaceuticals by 38.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock valued at $147,277,000 after purchasing an additional 677,098 shares in the last quarter. Finally, Polar Capital Holdings Plc raised its stake in shares of Apellis Pharmaceuticals by 126.6% in the third quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock valued at $40,089,000 after purchasing an additional 588,875 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).